Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial)

BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX;...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chest
Autors principals: Papaioannou, Alexandra, Kennedy, Courtney C., Freitag, Andreas, Ioannidis, George, O’Neill, John, Webber, Colin, Pui, Margaret, Berthiaume, Yves, Rabin, Harvey R., Paterson, Nigel, Jeanneret, Alphonse, Matouk, Elias, Villeneuve, Josee, Nixon, Madeline, Adachi, Jonathan D.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104558/
https://ncbi.nlm.nih.gov/pubmed/18641106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.08-0608
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars